Aus dem Abstract book der Veranstaltung: 7th European Workshop on Cannabinoid Research and IACM 8th Conference on Cannabinoids in Medicine, 17-19 September 2015 in Sestri Levante, Italy. cannabinoidconference2015.org

Autoren:

Eva Milz 1 , Franjo Grotenhermen 2,3
1 Medical Practice for Psychiatry and Psychotherapy, Berlin, Germany; 2 Nova-Institute Hürth/Rheinland, Germany; 3 Medical Practice, Rüthen, Germany

Background:

Attention deficit hyperactivity disorder [ADHD] may persist into adulthood. It may be treatment resistant to standard medication, that is methylphenidate, amphetamine derivatives and atomoxetine. Currently, no clinical studies have been conducted on cannabis-based medicines in ADHD, but a few case reports (Strohbeck-Kuehner P, et al. Cannabinoids 2008;3(1):1-3. Available online at http://cannabis-med.org/data/pdf/en_2008_01_1.pdf) and basic research (Adriani W, et al. Neurosci Biobehav Rev 2003;27:639-651.) suggest therapeutic benefits in this condition.

In Germany, patients independent of medical condition may apply for an approval to use cannabis flowers from the pharmacy if the standard therapy of a certain disease or symptom is not efficient or associated with severe side effects. Weiterlesen